EGFR and adenocarcinoma: The analysis of EGFR mutations is important for the diagnosis and treatment decision in NSCLC, especially adenocarcinoma, as EGFR mutations are a potential predictive biomarker for the EGFR-TKI therapy response (Zhou and Christiani, 2011; Shi et al., 2015).